Receive our newsletter – data, insights and analysis delivered to you
June 14, 2009

VIA and FDA Meet on Cardiovascular Drug

VIA Pharmaceuticals has met FDA authorities for guidance on the next phase for its lead cardiovascular drug VIA-2291 (atreleuton). The company reviewed safety and biological activity data from the Via-2291 phase 2 CEA and ACS trials with the FDA and has received guidance including on the

By cms admin

VIA Pharmaceuticals has met FDA authorities for guidance on the next phase for its lead cardiovascular drug VIA-2291 (atreleuton).

The company reviewed safety and biological activity data from the Via-2291 phase 2 CEA and ACS trials with the FDA and has received guidance including on the phase 3 trial design.

The phase study will assess the effect of Via-2291 in preventing cardiovascular events such as heart attack, stroke and cardiovascular mortality in patients with recent heart attack and/or established atherosclerotic cardiovascular disease.

Guidance from the FDA will also be incorporated into the Via-2291 registration and phase 3 programmes.

The company intends to submit its proposed phase 3 plan to the FDA including a request for a special protocol assessment.

VIA president and CEO Larry Cohen said VIA-2291 specifically targets the inflammation in atherosclerotic plaque that is thought to trigger major adverse cardiac events.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

“We believe this compound is now ready for testing in a broad outcome phase 3 trial that may establish a link between inflammation and reduction of these major adverse cardiac events,” Cohen said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU